Antihypertensive Drugs and Cancer Risk: Is There a Link?
Five antihypertensive drug classes were analyzed separately and were also compared to all other treatment groups, including placebo.
Five antihypertensive drug classes were analyzed separately and were also compared to all other treatment groups, including placebo.
Hydrochlorothiazide is indicated for the management of hypertension either as the sole therapeutic agent, or in combination with other antihypertensives.
[Cancer Management and Research] Researchers sought to determine if apatinib-related hypertension was a predictor of drug efficacy in patients with advanced HCC.
A study has shown that female cancer survivors may have a higher risk of cardiac events with some antihypertensive medications.
Ibrutinib-related hypertension associated with increased risk for major adverse cardiovascular events.
In this prospective study, researchers investigated the incidence of pulmonary hypertension among patients with MPNs. Their results led them to recommend systematic screening in this patient population.
The FDA is working in close collaboration with global regulatory partners to evaluate the controls in place and publish guidance on preventing unacceptable levels of nitrosamine in drugs.
Publication of the JNC 8 introduces a lower threshold for initiating hypertension treatment during cancer therapy.
Precise blood pressure level and time points at which intervening with antihypertensives was associated with a decreased risk of death.
Chronic hypertension may increase a person’s risk for developing glaucoma.